Mindset Pharma Inc. News Releases

Mindset Pharma Announces Closing of Arrangement

Fri, 27 Oct 2023 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October 19, 2023, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through its wholly-owned subsidiary Otsuka America, Inc. ("OAI") has acquired all of the issued and outstanding common shares (each, a "Common Share") in the capital of the Company pursuant to...

Mindset Pharma Announces Receipt of Final Order

Wed, 25 Oct 2023 18:59:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5, 2023, and October 19, 2023, the Company has obtained the final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Plan of Arrangement") under Division 5 of Part 9 of the Business...

Mindset Pharma Announces Shareholder Approval of Arrangement

Thu, 19 Oct 2023 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 19, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023, that the special resolution (the "Special Resolution") in connection with their previously announced statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under Division...

Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement

Thu, 05 Oct 2023 17:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") wishes to clarify certain disclosure in its management information circular (the "Circular") dated September 19, 2023 for its special meeting of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under...

Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order

Fri, 22 Sep 2023 17:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related materials were mailed today, September 22, 2023, for its special meeting (the "Meeting") of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among...

Otsuka Pharmaceutical to Acquire Mindset Pharma

Thu, 31 Aug 2023 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 31, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, announce that they have entered into a definitive arrangement agreement (the "Agreement") pursuant to which Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through its wholly- owned...

Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder

Thu, 22 Jun 2023 09:06:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the "MHRA") and the Research Ethics Committee to...